Schroder UK Public Private Trust PLC - London-based investor in mid to large sized quoted and unquoted companies - Agrees to sell basket of seven assets to Rosetta Capital V1 LP, an investment fund managed by science venture capital firm Rosetta Capital Ltd for GBP49.0 million. Says the sale portfolio consists of entire holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma, and partial holdings in Inivata, Immunocore and UK-listed ReNeuron Group PLC. Notes the deal represents a 22% discount to the valuation for those holdings reflected in the net asset value as at September 30.
"We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata, and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the company's holdings in delivering sustainable value and positive long-term shareholder returns," says Tim Creed and Ben Wicks, Schroder UK Public Private Portfolio Managers.
Current stock price: 34.86 pence
Year-to-date change: up 12%
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)